Skip to content

Study · Non-randomized trial · n = 6 · 2002

8 results

A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.

Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ

The Journal of clinical endocrinology and metabolism1 Apr 2002Cited by 49 (Europe PMC)

PMID11932320 (opens in a new tab)DOI10.1210/jcem.87.4.8432 (opens in a new tab)PepBankPUB-11932320
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, pegvisomant had no effect on glucose tolerance during oral glucose testing and a standard meal.

    In plain wordsIn healthy men, pegvisomant did not change glucose tolerance from baseline during glucose testing and a meal.

    Peptide
    Pegvisomant
    Outcome
    No significant changeGlucose tolerance
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 mg/d · 7 dAs given in this study (human).

    Source sentences

    Summary
    Pegvisomant had no effect on glucose tolerance or stimulated gut hormone response during an oral glucose tolerance test and a standard meal.
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.
  2. 02HumanNon-randomized trialMechanism

    In healthy men, pegvisomant had no effect on stimulated gut hormone responses during oral glucose testing and a standard meal.

    In plain wordsIn healthy men, pegvisomant did not change stimulated gut hormone responses from baseline during glucose testing and a meal.

    Peptide
    Pegvisomant
    Outcome
    No significant changeStimulated gut hormone response
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    20 mg/d · 7 dAs given in this study (human).

    Source sentences

    Summary
    Pegvisomant had no effect on glucose tolerance or stimulated gut hormone response during an oral glucose tolerance test and a standard meal.
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy men, octreotide significantly increased fasting plasma glucose.

    In plain wordsIn healthy men, octreotide increased fasting blood glucose from baseline.

    Peptide
    Octreotide
    Outcome
    IncreaseFasting plasma glucose
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 microg thrice daily · 7 dAs given in this study (human).

    Source sentences

    Summary
    In contrast, octreotide significantly increased fasting plasma glucose, lowered fasting plasma insulin, and led to deterioration in glucose tolerance;
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.
  4. 04HumanNon-randomized trialMechanism

    In healthy men, octreotide lowered fasting plasma insulin.

    In plain wordsIn healthy men, octreotide lowered fasting insulin from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseFasting plasma insulin
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 microg thrice daily · 7 dAs given in this study (human).

    Source sentences

    Summary
    In contrast, octreotide significantly increased fasting plasma glucose, lowered fasting plasma insulin, and led to deterioration in glucose tolerance;
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy men, octreotide worsened glucose tolerance.

    In plain wordsIn healthy men, octreotide worsened glucose tolerance from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseGlucose tolerance deterioration
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 microg thrice daily · 7 dAs given in this study (human).

    Source sentences

    Summary
    In contrast, octreotide significantly increased fasting plasma glucose, lowered fasting plasma insulin, and led to deterioration in glucose tolerance;
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.
  6. 06HumanNon-randomized trialSafety outcome

    During octreotide treatment, three healthy male subjects developed impaired glucose tolerance by World Health Organization criteria.

    In plain wordsDuring octreotide treatment, three healthy men developed impaired glucose tolerance.

    Peptide
    Octreotide
    Outcome
    IncreaseImpaired glucose tolerance
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    50 microg thrice daily · 7 dAs given in this study (human).

    Measurements

    Subjects with impaired glucose tolerance
    3 subjects
    during octreotide, 6 healthy men

    Source sentences

    Summary
    three subjects developed impaired glucose tolerance and one diabetes mellitus by World Health Organization criteria.
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.
  7. 07HumanNon-randomized trialSafety outcome

    During octreotide treatment, one healthy male subject developed diabetes mellitus by World Health Organization criteria.

    In plain wordsDuring octreotide treatment, one healthy man developed diabetes.

    Peptide
    Octreotide
    Outcome
    IncreaseDiabetes mellitus
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    50 microg thrice daily · 7 dAs given in this study (human).

    Measurements

    Subjects with diabetes mellitus
    1 subjects
    during octreotide, 6 healthy men

    Source sentences

    Summary
    three subjects developed impaired glucose tolerance and one diabetes mellitus by World Health Organization criteria.
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.
  8. 08HumanNon-randomized trialMechanism

    In healthy men, octreotide significantly impaired stimulated release of cholecystokinin, gastrin, insulin, and pancreatic polypeptide.

    In plain wordsIn healthy men, octreotide reduced stimulated release of cholecystokinin, gastrin, insulin, and pancreatic polypeptide from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseStimulated hormone release
    Study

    n = 6

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    50 microg thrice daily · 7 dAs given in this study (human).

    Source sentences

    Summary
    Octreotide significantly impaired stimulated release of cholecystokinin, gastrin, insulin, and pancreatic polypeptide.
    2 context sentences
    Summary · context
    We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study.
    Summary · context
    Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.